Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

NCT05689372 · Enrolling by invitation

Last updated 2026-05-28

This study is observing the safety and effectiveness of the diabetes medication Ozempic (semaglutide) in adults with type 2 diabetes in real-world clinical settings in Korea.

Status Enrolling by invitation Only people invited by the researchers can join.

Type Observational

Participants 600 people Planned (estimated).

Who can join Ages 19+ · all sexes

Timeline Started 2026-02 · est. completion 2027-05

Where 1 site · South Korea

What this study is testing ClinicalTrials.gov NCT05689372 ↗

Description as written by the study sponsor.

The aim of this study is to assess the safety and effectiveness of Ozempic initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Ozempic as prescribed by study doctor. The study will last for about 26 weeks.

Treatments tested

Semaglutide also known as Ozempic Drug

Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the K-PI.

Main thing measured	Number (incidence) of adverse events (AEs)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05689372 ↗